艾伯维旗下新药获重要药品监管机构认定 艾伯维公司于5月24日宣布，其候选药物upadacitinib获得国家药品监督管理局药品审评中心(CDE)突破性治疗药物 ...

Upadacitinib demonstrated significant clinical and endoscopic remission in Crohn's disease patients, including those with prior advanced therapy exposure, without new safety signals. The study ...

Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily ...

The FDA has approved upadacitinib to treat adults with giant cell arteritis. It is the second drug to be specifically approved for the disease in the United States after tocilizumab in 2017.

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common ...

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

That drug is upadacitinib, already under review by the FDA in moderate to severe rheumatoid arthritis, with a decision due from the FDA in the coming months after the regulator granted a faster ...

They are venetoclax and azacitidine to treat acute myeloid leukaemia, ibrutinib for chronic lymphocytic leukaemia, and upadacitinib (brand name Rinvoq) to treat eczema, ulcerative colitis ...